These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20460889)

  • 1. Approaches towards individualized immune intervention.
    Giese T; Sommerer C; Zeier M; Meuer S
    Dig Dis; 2010; 28(1):45-50. PubMed ID: 20460889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring immunosuppression with measures of NFAT decreases cancer incidence.
    Giese T; Sommerer C; Zeier M; Meuer S
    Clin Immunol; 2009 Sep; 132(3):305-11. PubMed ID: 19398376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell mediated immunity (CMI) and post transplant viral infections--role of a functional immune assay to titrate immunosuppression.
    Gautam A; Fischer SA; Yango AF; Gohh RY; Morrissey PE; Monaco AP
    Int Immunopharmacol; 2006 Dec; 6(13-14):2023-6. PubMed ID: 17161357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
    Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
    Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancers after renal transplantation.
    Wong G; Chapman JR
    Transplant Rev (Orlando); 2008 Apr; 22(2):141-9. PubMed ID: 18631867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of cancer after immunosuppressive treatment for heart transplantation.
    Ippoliti G; Rinaldi M; Pellegrini C; Viganò M
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):101-13. PubMed ID: 15979322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Solid tumors after kidney transplantation].
    Moal MC
    Nephrol Ther; 2008 Oct; 4 Suppl 3():S214-7. PubMed ID: 19000890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimization of immunosuppression in kidney transplantation.
    Augustine JJ; Hricik DE
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):535-41. PubMed ID: 18089967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling the incidence of infection and malignancy by modifying immunosuppression.
    Soulillou JP; Giral M
    Transplantation; 2001 Dec; 72(12 Suppl):S89-93. PubMed ID: 11833147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can immune monitoring help to minimize immunosuppression in kidney transplantation?
    Ashton-Chess J; Giral M; Soulillou JP; Brouard S
    Transpl Int; 2009 Jan; 22(1):110-9. PubMed ID: 18764832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of living kidney transplantation from HLA-identical sibling donors under calcineurin inhibitor immunosuppression.
    Shimmura H; Tanabe K; Ishida H; Miyamoto N; Tokumoto T; Ishikawa N; Toma H
    Int J Urol; 2006 May; 13(5):502-8. PubMed ID: 16771716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
    Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
    Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer incidence after immunosuppressive treatment following kidney transplantation.
    Andrés A
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):71-85. PubMed ID: 15978827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urological malignancy after renal transplantation.
    Besarani D; Cranston D
    BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of immunosuppression--what patients really think.
    Newstead CG
    Nephron Clin Pract; 2004; 97(2):c31-2. PubMed ID: 15218326
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial immunosuppression in liver transplant recipients with impaired renal function.
    Varo E; López A; Rivero C
    Transplant Proc; 2005 Nov; 37(9):3909-12. PubMed ID: 16386581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.